Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Industry Reiterates Call for Careful Discussions on Off-Year Revision: LDP Confab
November 10, 2022
- 9-Valent HPV Vaccine Program to Start in April, Panel Seeks Early Approval of 2-Dose Regimen
November 9, 2022
- Bill to Amend Infectious Disease Act Clears Lower House
November 9, 2022
- Pharma, Payers Nudge MHLW to Speed Up Data Supply from NDB
November 9, 2022
- MOF Panel Member Calls for Drug Price Cuts to Unleash Innovation, Ease Household Burdens
November 8, 2022
- Japan Panel Recognizes 6 More Deaths Possibly Linked to COVID Vaccines
November 8, 2022
- MOF Proposes Transition to Normal Framework for COVID Vaccines, Therapeutics
November 8, 2022
- MOF Renews Its Push for Full Drug Price Revision in FY2023
November 8, 2022
- Lower House Health Committee OKs Revised Bill to Amend Infectious Disease Act
November 7, 2022
- CEFP Will Thoroughly Discuss Drug Pricing and Discovery: Minister
November 4, 2022
- Moderna’s BA.4/5 COVID Booster Nabs Special Approval in Japan
November 1, 2022
- Label Expansion for TS-1, Enhertu and More in Line for November Approval
November 1, 2022
- MHLW Panel Puts Pfizer’s Precedex on Hold for Pediatric Indication
October 31, 2022
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Aricept’s Lewy Body Dementia Indication to Be Modified after Post-Launch Trial Miss
October 31, 2022
- MHLW Panel OKs 100 More Health Damage Claims for COVID-19 Vaccines
October 31, 2022
- Japan Adopts Stimulus Package, Set to Support Domestic API Production
October 31, 2022
- Think Tanks Propose New Pricing Methods for Innovative Meds, Multi-Faceted Evaluations
October 28, 2022
- Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
October 28, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Adeno-associated virus (AAV) gene therapies have long been viewed as carrying only a minimal risk of insertional mutagenesis — a…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…